MetaVia (MTVA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
8 Jun, 2026Opening remarks and agenda
Meeting called to order by the CEO, with five items of business on the agenda, including director elections, auditor ratification, reverse stock split, equity plan amendment, and potential adjournment for additional proxy solicitation.
Introduction of board members and confirmation of meeting rules and materials available online.
Board and executive committee updates
Two Class I directors, D. Gordon Strickland and Dr. James Tursi, were nominated for election to serve three-year terms.
Current directors and board chair were introduced to attendees.
Shareholder proposals
Proposals included electing directors, ratifying the auditor, approving a reverse stock split, amending the equity incentive plan, and authorizing adjournment if needed for further proxy solicitation.
Voting procedures and eligibility were explained, with digital voting available during the meeting.
Latest events from MetaVia
- Q2 2026 net loss was $5.3M, R&D costs rose, and cash stood at $12.6M amid funding concerns.MTVA
Q2 2026 - Advancing next-gen obesity and MASH therapies with strong clinical data and near-term catalysts.MTVA
Investor presentation - Promising dual-action obesity and MASH therapies approach key data and partnership milestones.MTVA
Life Sciences Virtual Investor Forum - DA-1726 and vanoglipol show strong clinical and combination potential, with solid cash runway.MTVA
Emerging Growth Conference 93 - Strong clinical pipeline in obesity and MASH targets high-growth markets with near-term catalysts.MTVA
Investor presentation - Q1 2026 net loss was $3.8M; cash at $13.7M; clinical progress and going concern risk remain.MTVA
Q1 2026 - Annual meeting to vote on directors, auditor, reverse split, and equity plan amendment.MTVA
Proxy filing - Annual meeting to vote on director elections, reverse split, equity plan, and auditor ratification.MTVA
Proxy filing - Promising obesity and MASH therapies advance with strong early data and major market potential.MTVA
Investor presentation